Amit Singal, MD, UT Southwestern Medical Center

Articles

Optimizing Precision Medicine in HCC

October 1st 2021

Takeaways from a discussion on treatment advances in hepatocellular carcinoma.

Biomarkers to Guide HCC Treatment Decisions

October 1st 2021

Professionals who treat patients with hepatocellular carcinoma comment on the need for more research and biomarkers to fuel treatment decisions.

Second-Line Treatment Approaches for Advanced HCC

September 24th 2021

An overview of the second-line treatment landscape for patients with advanced hepatocellular carcinoma and considerations regarding the sequencing of novel therapies.

The COSMIC-312 Study in Advanced HCC

September 24th 2021

Thoughts regarding the COSMIC-312 study of cabozantinib plus atezolizumab as frontline therapy for advanced hepatocellular carcinoma.

HCC: IO in Liver Transplant Recipients

September 17th 2021

A debate regarding the appropriateness of immunotherapy following liver transplantation in patients with hepatocellular carcinoma.

The LEGACY Study in HCC

September 17th 2021

Implications on treatment practices of the LEGACY study of Y-90 glass microspheres in patients with unresectable solitary hepatocellular carcinoma.

Selecting First-Line Therapy for Advanced HCC

September 10th 2021

An overview of factors that deem patients appropriate for atezolizumab/bevacizumab vs lenvatinib or sorafenib as frontline therapy for advanced hepatocellular carcinoma.

Frontline IO for Advanced HCC

September 10th 2021

Considerations regarding the use of nivolumab as frontline treatment for advanced hepatocellular carcinoma.

Systemic Treatment Advances for Advanced HCC

September 3rd 2021

Exciting developments using novel therapies as systemic treatment for advanced hepatocellular carcinoma.

Scoring/Classifying Patients With Advanced HCC

September 3rd 2021

Best practices using available scoring systems to evaluate and treat patients with advanced hepatocellular carcinoma.

Adjuvant Treatment Advances in Operable HCC

August 27th 2021

Perspectives regarding treatment advances using adjuvant approaches that include immunotherapy to treat early-stage hepatocellular carcinoma.

Hepatic Arterial Infusion Chemotherapy for HCC

August 27th 2021

Reactions to recent clinical abstracts that support the use of hepatic arterial infusions for chemotherapy delivery in hepatocellular carcinoma.

Neoadjuvant Therapy to Downstage HCC

August 20th 2021

Reactions to treatment gaps in the neoadjuvant space for hepatocellular carcinoma and implications for incorporating data supporting newer, novel systemic therapies for appropriate patients.

Advances in Locoregional Therapy for Early Stage HCC

August 20th 2021

University of Arizona’s Rachna Shroff, MD, describes the role of systemic therapy with locoregional treatment for early stage hepatocellular carcinoma and highlights treatment strategies of interest that remain under investigation.

Current Role of Locoregional Therapy for Early Stage HCC

August 13th 2021

Edward Kim, MD, of Mount Sinai Health System describes where advances in locoregional therapy for early-stage hepatocellular carcinoma fit into the therapeutic landscape.

Diagnosing Early-Stage HCC via Biopsy

August 13th 2021

A debate regarding the current role of biopsy to confirm a diagnosis of early-stage hepatocellular carcinoma.

Diagnostic Testing for Early Stage HCC

August 6th 2021

The rationale for diagnostic imaging to evaluate and diagnose early stage hepatocellular carcinoma.

Screening for Early Stage HCC

August 6th 2021

A brief overview of criteria and tools used to assess, and risk stratify patients with early stage hepatocellular carcinoma.

Future Directions of HCC

April 14th 2021

Stephen L. Chan, MD; Masatoshi Kudo, MD, PhD; and Amit Singal, MD, discuss the future treatment landscape for the management of HCC (hepatocellular carcinoma).

Using AFP as a Biomarker in HCC

April 14th 2021

Stephen L. Chan, MD, comments on the use of AFP as a predictive biomarker in HCC (hepatocellular carcinoma) and the current use of ramucirumab.